Companies › Lantheus Medical Imaging
4 active drug programs in 4 registered trials: 2 Phase 1, 1 Phase 4, 1 Phase 2; Oncology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Piflufolastat F 18 Prostate-specific membrane antigen (PSMA)-targeting PET imaging agent | PSMA | Phase 4 | Prostate Cancer | – |
| [68Ga]-LNTH-2401 PSMA-targeting positron emission tomography (PET) imaging agent | PSMA1 | Phase 2 | Prostate Cancer | Sep 2029 |
| LNTH-2403 177Lu-labeled targeted osteosarcoma therapy (mechanism not specified in registry) | – | Phase 1 | Relapsed / Refractory Osteosarcoma | Aug 2027 |
| 64Cu-LNTH-1363S FAP inhibitor radiolabeled with Copper-64 (64Cu) for PET/CT imaging | FAP | Phase 1 | Metastatic Sarcoma | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06298916 | 64Cu-LNTH-1363S | Phase 1 | Metastatic Sarcoma | Oncology | Nov 2025 |
| NCT06074510 | Piflufolastat F 18 | Phase 4 | Prostate Cancer | Oncology | Sep 2026 |
| NCT07357519 | LNTH-2403 | Phase 1 | Relapsed / Refractory Osteosarcoma | Oncology | Aug 2027 |
| NCT07831824 | [68Ga]-LNTH-2401 | Phase 2 | Prostate Cancer | Oncology | Sep 2029 |
Blue Earth Diagnostics Chengdu New Radiomedicine Technology Clarity Pharmaceuticals Norroy Bioscience SOFIE
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.